PBLS · XBRL financial data
Parabilis Medicines financial statements, every quarter
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In millions of dollars | Jun 30, 2026 |
|---|---|
| Revenue | 0 |
| Research and development | 39 |
| General and administrative | 12 |
| Total operating expenses | 51 |
| Operating income (loss) | (51) |
| Interest expense | 0 |
| Net income (loss) | (52) |
| Earnings per share, basic USD per share | (2.32) |
| Earnings per share, diluted USD per share | (2.32) |
| Weighted average shares, basic millions of shares | 29 |
| Weighted average shares, diluted millions of shares | 29 |
Balance sheet
CSVFiscal quarters
| In millions of dollars | Jun 30, 2026 |
|---|---|
| Cash and cash equivalents | 1,087 |
| Marketable securities | 34 |
| Prepaid and other current assets | 5 |
| Total current assets | 1,125 |
| Property and equipment, net | 7 |
| Right-of-use asset | 36 |
| Total assets | 1,175 |
| Accounts payable | 19 |
| Accrued liabilities | 20 |
| Current portion of long-term debt | 6 |
| Total current liabilities | 63 |
| Long-term debt | 1 |
| Lease liability, non-current | 32 |
| Total liabilities | 128 |
| Accumulated deficit | (639) |
| Total stockholders' equity | 1,048 |
| Total liabilities and equity | 1,175 |
| Common shares outstanding (cover page) millions of shares | 122 |
Cash flows
CSVFiscal quarters
| In millions of dollars | Jun 30, 2026 |
|---|---|
| Net income (loss) | (52) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Parabilis Medicines | 1,087 | 0.1 | not reported | 121.9M | — | 10-QJun 30, 2026 |
| Dare Bioscience | 13 | 0.2 | (6.8)* | 15.3M | 1.9 quarters | 10-QJun 30, 2026 |
| Lipocine | 5 | 0.2 | (3)* | 8.2M | 7.7 quarters | 10-QJun 30, 2026 |
| Clearside Biomedical | 6.8 | 0.2 | (5.5)* | 5.2M | 1.2 quarters | 10-QSep 30, 2025 |
| Cocrystal Pharma | 2.2 | 0.1 | (2.5)* | 19.3M | 0.9 quarters | 10-QJun 30, 2026 |
| Cardiff Oncology | 9.2 | 0.1 | (12)* | 77.8M | 2.9 quarters | 10-QJun 30, 2026 |
| Yarrow Bioscience | 23 | 0.1 | (2)* | 2.7M | 11.5 quarters | 10-QJun 30, 2026 |
| Decoy Therapeutics | 8.3 | 0.2 | (2.7)* | 655,185 | 3.1 quarters | 10-QJun 30, 2026 |
| Scorpius Holdings | 0.6 | not reported | (2.9)* | 61.1M | 0.2 quarters | 10-QSep 30, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.